Ocular Therapeutix™ to Host Investor Day on September 30, 2025

Core Insights - Ocular Therapeutix, Inc. will host an Investor Day on September 30, 2025, in New York City to discuss the AXPAXLI™ wet AMD registrational program and its global commercial opportunities [1][2] - The event will feature presentations from senior leadership and discussions with global retina Key Opinion Leaders (KOLs) [2] Company Overview - Ocular Therapeutix, Inc. is an integrated biopharmaceutical company focused on redefining the retina experience [15] - AXPAXLI™ (OTX-TKI) is an investigational product candidate for retinal disease currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) [16] Event Details - The Investor Day will include a live Q&A session and a networking reception for in-person attendees [2] - A live webcast of the presentation will be available on the company's website, with a replay archived for at least 30 days [3] Key Opinion Leaders - Dr. Arshad M. Khanani, a prominent figure in clinical research for retinal diseases, will participate in the event [4][5] - Professor Adnan Tufail, with extensive experience in retinal conditions, will also be a key speaker [9][10] - Dr. Eleonora Lad, known for her work in early diagnosis and treatment of retinal diseases, will contribute to the discussions [11][12] - Dr. Patricio G. Schlottmann, an ophthalmologist and researcher from Argentina, will be involved as well [13][14] Clinical Strategy - Presentations will cover the complementary SOL trials and their potential to support a differentiated superiority label for AXPAXLI in wet AMD [2] - The company will outline its clinical strategy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME) [2] Commercial Opportunity - The event will review the global commercial opportunity for AXPAXLI across various retinal indications [2]